Comments
Natco Pharma today said it has launched generic Hepcinat LP, which is in the treatment of chronic hepatitis C infection in adults, in Nepal.
NATCO priced its generic medicine, Hepcinat LP, at Rs 25,000 for a bottle of 28 tablets in Nepal, the company said in a filing to the BSE.
Hepcinat LP is generic version of Ledipasvir and Sofosbuvir combination and is used in the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.
Natco had signed a non—exclusive licensing agreement with Gilead Sciences earlier in 2015, to manufacture and sell generic versions of its chronic hepatitis C medicines, including generic version of HARVONI, in India and other 100 developing countries.
Shares of the company were trading marginally up at Rs 2,567 on BSE in afternoon trade.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.